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Madrid, SpainAbstractAntifungal stewardship (AFS) programmes are needed in tertiary-care hospitals. Our aim is to describe a bedside non-restrictive AFS
programme, and to evaluate its economic impact. During the ﬁrst year of the AFS a bundle of non-interventional measures were
implemented. During the second year an infectious diseases specialist visited 453 patients receiving candins, liposomal amphotericin B,
voriconazole or posaconazole. Monthly costs were studied with an interrupted time series (ITS) analysis. The main prescribing
departments were haematology (35%), medical departments (23%), and intensive care units (20%). Reasons to start antifungal therapy
were: targeted therapy (36%), prophylaxis (32%), empirical therapy (20%) and pre-emptive therapy (12%). At the initial visit, diagnostic
advice was provided in 40% of cases. The most common therapeutic recommendations were to de-escalate the antifungal drug (17%) or
to suspend it (7%). Annual total antifungal expenditure was reduced from US$3.8 million to US$2.9 million over the ﬁrst 2 years,
generating net savings of US$407,663 and US$824,458 per year after considering the cost of additional staff required. The ITS analyses
showed a signiﬁcant economic impact after the ﬁrst 12 months of the intervention (p 0.042 at month 13), which was enhanced in the
following 24 months (p 0.006 at month 35). The number of deﬁned daily doses decreased from 66.4 to 54.8 per 1000 patient-days.
Incidence of candidaemia was reduced from 1.49 to 1.14 (p 0.08) and related mortality was reduced from 28% to 16% (p 0.1). A
collaborative and non-compulsory AFS program based on bedside intervention is an efﬁcacious and cost-effective approach that optimizes
the use of AF drugs.
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p://dx.doi.org/10.1016/j.cmi.2015.01.013IntroductionThe high mortality and diagnostic challenge of invasive fungal
infections (IFIs) have encouraged the use of broad-spectrum
and costly antifungal agents. These drugs are frequently pre-
scribed as pre-emptive or empirical treatments, sometimes
with questionable indications [1].
Antimicrobial stewardship programmes are considered an
essential part of policies to enhance safety and are endorsed by
scientiﬁc societies [2]. Although signiﬁcant success has beenious Diseases. Published by Elsevier Ltd. All rights reserved
CMI Valerio et al. Antifungal stewardship 492.e2demonstrated with antibacterial stewardship interventions,
experience with antifungal drugs is scarce. Some programmes
include formulary restriction and preauthorization re-
quirements [3–5] or did not include all available antifungal
agents [6–8]. Nowadays, when competition for resources is
huge and proof of return on investment is a requisite, the cost-
effectiveness and safety of antifungal stewardship programmes
(AFSPs) need to be demonstrated.
We describe the design, implementation and assessment of a
non-compulsory, multidisciplinary AFSP performed over a 2-
year period in a tertiary-care hospital. Our objectives were
to describe the implementation of the AFSP and to evaluate its
impact on costs. The most common causes of misuse of anti-
fungal drugs in a general hospital were also analysed.Materials and methodsStudy design
This was a quasi-experimental study with a time series design.
The primary outcome of the study was the reduction in anti-
fungal expenditure. Secondary outcomes included assessment
of the percentage of appropriate antifungal prescriptions, can-
didaemia incidence, candidaemia mortality rate, and percentage
of ﬂuconazole resistance. ORION guidelines [9] and TIDieR
checklist [10] were fulﬁlled.
Background
Our AFSP was conducted at Gregorio Marañón Hospital, a
general tertiary-care teaching hospital with 1550 beds serving a
population of 750 000 inhabitants in Madrid, Spain, with
approximately 65 000 admissions per year. The hospital is a
referral centre for solid organ transplantation, heart surgery,
oncology (38 beds), haematology (13 beds), bone marrow
transplantation (eight beds), and HIV/AIDS care. It has ﬁve
intensive care units (ICU: three for adults and two for paediatric
patients (approximately 96 intensive care beds)). Adult and
paediatric infectious diseases consultation services are readily
available (210–275 formal consultations per month).
Available diagnostic tools include fungal cultures, sensitivity,
serological (galactomannan, Candida albicans germ tube anti-
bodies (CAGTA), Platelia™ Candida and cryptococcal antigen)
and molecular tests (Aspergillus PCR). Histopathology exami-
nation, computed tomography scans and magnetic resonance
imaging are also available.
Approximately 1500 patients receive systemic antifungal
drugs every year, and annual antifungal purchasing costs
increased from US$3.5 million in 2007 to over US$4.4 million
in 2009 (26% increase) (data from the Pharmacy Department).
In response to the need for more appropriate use of antifungalClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Inagents, an AFSP was started in October 2010. By October
2011, the programme was fully implemented. The study was
approved by the hospital’s institutional review board, the
pharmacy and infectious diseases committees, and by the anti-
microbial subcommittee.
Steps of the antifungal stewardship programme
Our AFSP consisted on two phases: a ﬁrst-year intervention
and a second-year intervention.
First-year intervention. The ﬁrst-year intervention ran from 1
October 2010 till September 2011, as follows:
(1) We created a multidisciplinary collaborative group on
mycosis (COMIC Study group) including all departments
involved in IFIs, supported by the hospital administration.
This group was responsible for assessing the
epidemiology of fungal infections, suggested preventive
and therapeutic interventions and proposed standards
and local guidelines. Periodic meetings were
programmed, and resources were obtained to
incorporate an infectious diseases physician, a pharmacist
and a data manager with 50% dedication to the
programme (approximately 4 h/day).
(2) The COMIC study group prepared and distributed local
pocketsize clinical guidelines for the diagnosis and
treatment of IFIs (October 2010 to March 2011). The
guidelines were also approved by the pharmacy
committee and by the antimicrobial therapy team.
(3) In April 2011, we implemented a non-compulsory
Computerized Physician Order Entry system (April 2011),
which alerted pharmacists about new antifungal
prescriptions and provided real-time alerts to prescribers
of potential drug interactions and costs. The programme
required justiﬁcation of the indication according to local
guidelines and provided information about the diagnosis
and treatment of IFIs and reminders for determination of
voriconazole and posaconazole levels. The Computerized
Physician Order Entry tool allowed the possibility of
prescriptions that did not fulﬁl local indications.
(4) We ran a survey to evaluate physicians’ knowledge of the
principal prescribing departments involved in the diagnosis
and management of IFIs (October 2010 to November
2010). This information was used to design interactive
training courses based on clinical cases. A 20-point
questionnaire was administered to all participants before
and after the course to evaluate the impact and
effectiveness of the course [11].
(5) We performed an audit of the use and cost of 100
antifungal prescriptions (December 2010 to January
2011) according to a quality score (scale of 0 to 10) forfectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 492.e1–492.e9
492.e3 Clinical Microbiology and Infection, Volume 21 Number 5, May 2015 CMIevaluation of the adequacy of the prescription (Table 1).
The audit enabled us to detect the main problems and
to calculate the potential cost-effectiveness of
implementing an AFSP [12].
(6) Throughout the ﬁrst-year intervention period, regular
meetings were held with the main prescribing
departments to report the interim and ﬁnal results and
to provide and receive feedback.
Second-year intervention. The second-year intervention ran from
October 2011 to September 2012. The AFSP team received
daily e-mail alerts from the Pharmacy Department on every
patient receiving candins, liposomal amphotericin B, vor-
iconazole and posaconazole. (ﬂuconazole, itraconazole and
ketoconazole were not considered as targets). All these pre-
scriptions were prospectively audited. The infectious diseases
specialists visited the patient and recorded data following a pre-
established protocol [12]. Patients receiving any of these anti-
fungal drugs were visited at least when the drug was ﬁrst
administered and when microbiological laboratory results
became available. The data collected included demographic in-
formation, underlying condition, antifungal prescribed (indica-
tion, dose and length of treatment), microbiological results,
adjustment of therapy, toxicity and outcome. The patient’s
progress was always discussed with the attending physician and
non-compulsory written diagnostic and therapeutic advice was
provided. There was also an intravenous–oral switch pro-
gramme performed by the AFSP team that suggested the change
to an oral antifungal, if possible, and a reminder in the
Computerized Prescription Order Entry. After discharge, the
outcome of the intervention was evaluated. The AFSP com-
mittee had monthly meetings where results, challenges and
upcoming ideas were analysed to assess whether the pro-
gramme was working. The results of the programme were
presented to the top prescribing departments and at theTABLE 1. Score for evaluating appropriateness of antifungal therap
Feature Question
Indication Did the patient need an antifungal?
Selection Did the antifungal cover the suspected fungi and wa
the ﬁrst option recommended by the guidelines?
Dosagea Was the dosage correct according to the body wei
hepatic and renal function, and potential interaction
with other drugs?
Microbiological adjustment Was the antifungal adjusted after microbiological res
(identiﬁcation of microorganism, antifungal
susceptibility
tests, and indirect tests) became available?
Administration route Was the intravenous route switched to the oral ro
when possible?
Duration Was the duration of therapy correct according to
the guidelines?b
Total score (From 0 to 10).
aBoth low and high doses were considered incorrect. Adjustment for renal and hepatic failu
monitoring of serum voriconazole and posaconazole was not available.
bDurations that were too short and too long were considered incorrect.
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and InfectCOMIC meetings. From September 2012, the AFSP continued
to act but data different from cost were not recorded.
Deﬁnitions
Antifungal therapy was classiﬁed as prophylaxis, empirical, pre-
emptive or targeted.
Prophylaxis. Prophylaxis was deﬁned as treatment prescribed to
a patient with risk factors for IFI but no clinical manifestations of
the disease.
Empirical therapy. In neutropenic patients, empirical therapy was
deﬁned as antifungal drugs administered to treat persistent fever in
cases were broad-spectrum antibacterial therapy had not pro-
duced positive microbiological results. In non-neutropenic pa-
tients, empirical therapywas deﬁned as antifungal therapy initiated
to treat suspected IFI with no positive microbiological results.
Pre-emptive therapy. In neutropenic patients, pre-emptive ther-
apy was deﬁned as early treatment for probable IFI based on
clinical or radiological data and/or positive biomarkers. In non-
neutropenic patients, pre-emptive therapy was deﬁned as
antifungal drugs administered to patients with clinical signs, risks
factors and a Candida score of more than two points [13].
Targeted therapy. This was deﬁned as treatment of a microbi-
ologically proven infection.
Candidaemia-related mortality. This was deﬁned as mortality
occurring within 1 month after the candidaemia episode.
Appropriateness of antifungal prescription. The criteria used to
deﬁne the appropriateness of antifungal prescription were
based on the guidelines of the Infectious Diseases Society of
America, the European Conference on Infections in Leukaemia
[14–16] and on local susceptibility patterns. Adequate dosage
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re and drug-to-drug interactions were also addressed. At the time of the study,
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consideration. The adequacy of antifungal use was evaluated
using a point score previously deﬁned by three senior infectious
diseases specialists and one senior pharmacist during three
consensus meetings. This adequacy score has a maximum of ten
points and was applied to assign a relative weight to each of the
items evaluated based on adequacy, efﬁciency and safety, as
follows: correct indication, optimal selection, correct dosage,
correct administration route, correct adjustment according to
microbiological results, and adequate length of therapy. The
score is detailed in Table 1 and was previously published by our
team. Any prescription with a global score other than 10 was
judged inappropriate [12]. Antifungal appropriateness was
assessed by the senior infectious diseases specialist and the
senior pharmacist specializing in mycology in charge of the
AFSP. Discordances were resolved by a second senior infec-
tious diseases specialist.
Antifungal toxicity. This was assessed in every intervention by
means of physical examination, review of the clinical chart and
of the laboratory results. In case of no other feasible justiﬁca-
tion of the abnormalities, adverse events were classiﬁed as
potentially related to the antifungal therapy.
Expenditure objectives and cost analysis
The expenditure objective for the AFSP was purposefully
conservative: to reduce total antifungal spending by at least 10%
annually in the inpatient setting. We used an opportunity
sampling (all patients treated during the study period). Given an
antifungal consumption of US$3.8 million during the 12 months
before implementation, this ﬁnancial goal would generate a net
saving of US$300 000 to US$350 000 per year after considering
the cost of additional staff required.
Toestimate the effect of theAFSPonantifungal consumption, an
interrupted time series analysis (ITS) with monthly AF cost data
was performed comparing 36 months preceding the imple-
mentation of the program (pre-intervention period) to the 36
months after its implementation. The last 12monthswere included
in the analysis to investigate the sustainability of the intervention
(see Supporting information: Interrupted time series analysis).
Antifungal drug costs were calculated prospectively based on
the actual dose administered and the drug acquisition costs for
each year. This price may differ from the ofﬁcially established
price, owing to discounts negotiated with antifungal drug sup-
pliers. All costs in euros were converted to US dollars, based
on the exchange rate at 30 September 2013 (V1 = US$1.35).
As complementary data, the deﬁned daily doses (DDDs)
were also provided by the Pharmacy Department. DDDs were
determined according to dosages recommended by the WHO
(http://www.whocc.no/atc_ddd_index/). A DDD is the average
maintenance dose per day for a drug in its main indication forClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Inadults. Because no DDD was suggested for liposomal ampho-
tericin B, we selected 200 mg, which was thought to represent
a typical daily dose for an adult with normal renal and hepatic
function. DDDs were expressed per 1000 patient-days.
Statistical analysis
Data were entered into a database created using MICROSOFT
ACCESS®. The qualitative variables appear with their frequency
distributions. Normally distributed quantitative variables are
expressed as the mean and standard deviation (SD); non-
normally distributed variables are expressed as the median
and interquartile range. The t-test or analysis of variance was
used to compare how scores differ according to department.
An ITS was conducted to detect whether or not the AFSP
had a signiﬁcant effect over the natural evolution of the time
series. This analysis permits the detection of changes in level
immediately after intervention, of differences between pre-
intervention and post-intervention slope and the estimation
of monthly average intervention effect after the intervention.
Finally, trends in rate of candidaemia per 1000 admissions
were evaluated using Poisson regression analysis. Proportions
were compared using Mantel–Haenstel chi-squared test.
A p value0.05 was considered statistically signiﬁcant. STATA/
SE 12.0 (StataCorp LP, 4905 Lakeway DriveCollege Station,
Texas, USA) and IBM SPSS STATISTICS 19.0 software (IBM
Corporation, 1 New Orchard Road Armonk, New York, USA)
were used for the statistical analysis and the interrupted time
series analysis.ResultsDemographic and clinical characteristics of patients
included in the bed-side approach (second year of
intervention)
From October 2011 to October 2012, systemic antifungal
therapy was prescribed to 1506 patients (30.5/1000 admis-
sions). After excluding 1053 patients who received ﬂuconazole,
the population of the second-year bedside intervention
comprised 453 patients treated with candins, voriconazole,
posaconazole or amphotericin. Patients were initially evaluated
an average of 3 days after antifungal prescription.
Invasive fungal infections was demonstrated in 131 patients
receiving antifungals (28.9%): 105 (23.2%) were caused by
yeasts, 25 (5.5%) by moulds, and one by both (0.2%). Overall,
155 microorganisms were isolated, and three patients were
diagnosed using only indirect tests (galactomannan) (see
Supporting information, Table S1).
Most patients were men (69.3%), and median age was 51
years (see Supporting information, Table S2). The mainfectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 492.e1–492.e9
TABLE 2. Diagnostic and therapeutic advice at the initial visit
and at discharge and evaluation of antifungal use
Advice n [ 453
Diagnostic advice at initial visit
No more tests required, n (%) 270 (59.6)
Diagnostic tests recommended, n (%) 183 (40.4)
Total number of diagnostic tests recommended 294
Blood and catheter cultures 106 (35.9)
Galactomannan, B-D glucan, and antifungal levels 58 (19.7)
BAL and other respiratory samples 51 (17.3)
Urine cultures 24 (8.1)
Biopsy 9 (3.1)
Others 5 (1.7)
Chest scan or magnetic resonance 41 (13.9)
Therapeutic advice at initial visit, n (%)
No change required 310 (68.4)
De-escalate the antifungal 79 (17.4)
Stop the antifungal 32 (7.1)
Escalate the antifungal 14 (3.1)
Modify the dose 12 (2.6)
Switch drug due to toxicity 2 (0.4)
Add a second antifungal 1 (0.2)
Evaluation of antifungal use at discharge
Inadequacy in any aspect of antifungal use, n (%) 203 (44.8)
Indication 20 (4.4)
Drug choice 109 (24.1)
Dosage 17 (3.8)
Adjustment to microbiology results 84 (18.5)
Sequential therapy 30 (6.6)
Length of therapy 129 (28.5)
Score for antifungal use at discharge
Overall (n = 453) 8.64 ± 1.81
Haematology (n = 156) 8.72 ± 1.82
Medical wards (n = 105) 8.97 ± 1.75
Intensive care (n = 90) 8.06 ± 1.84
Surgery (n = 47) 8.32 ± 2.06
Paediatrics (n = 36) 9.06 ± 1.30
Oncology (n = 19) 8.84 ± 1.34
Acceptance of AFS team recommendationsa, n (%)
No therapeutic adjustment of antifungal therapy required 245 (54.1)
Therapeutic adjustment required and made 110 (24.3)
Therapeutic adjustment required but not made 98 (21.6)
AFS, antifungal stewardship; BAL, bronchoalveolar lavage.
aThe acceptance of the AFS team recommendations is referred to therapeutic ones.
Overall, the compliance is 78.4%.
492.e5 Clinical Microbiology and Infection, Volume 21 Number 5, May 2015 CMIprescribing departments were haematology (34.4%), medical
departments (23.2%), and ICUs (19.9%) (Table S2). The in-
dications for prescribing antifungals were targeted therapy
(36.4%), prophylaxis (32.2%), empirical therapy (19.6%) and
pre-emptive therapy (11.7%).
After the ﬁnal review of the clinical charts, probable
antifungal-related toxicity was found in 31 cases (6.8%). Renal
toxicity was suspected in nine patients, all of whom received
liposomal amphotericin B. Hepatic toxicity was suspected in 18
patients: six were treated with posaconazole, two with caspo-
fungin, two with micafungin, and one with voriconazole. Median
hospital stay was 35 days, and in-hospital mortality was 26.9%
(9.3% IFI-related) (Table S2).
Use of restricted antifungal drugs
The most common antifungals prescribed were liposomal
amphotericin B (25.8%), micafungin (23.4%) and posaconazole
(17.0%) (see Supporting information, Table S3). A total of 167
patients (36.9%) received more than one drug, 128 (28.3%)
received two, 25 (5.5%) received three, and 14 (3.1%) were
treated with four different drugs. Median treatment duration
was 14 days (interquartile range 7–26).
We observed a relationship between main indication and
prescribing department: prophylaxis predominated in the hae-
matology unit (75.6% of prescriptions), pre-emptive treatment
in the ICUs (37.8%), and targeted therapy in the medical and
paediatric wards (72.4% and 63.9%, respectively).
There was also a clear relationship between drug and indi-
cation. Posaconazole (46.6%) and micafungin (34.2%) were the
preferred drugs for prophylaxis. Candins were widely used for
pre-emptive therapy, accounting for 47/53 treatments with this
indication (88.7%). Liposomal amphotericin B was mainly used
as targeted therapy (46.7%) and to treat leishmaniasis (31.6%).
Micafungin was the second most common antifungal drug used
for targeted therapy (17.6%) and for prophylaxis (34.2%).
Diagnostic and therapeutic advice at the initial visit
No diagnostic advice was deemed necessary in 270 patients
(59.6%), but 294 recommendations were made in the remaining
183 (40.4%) (Table 2). The most common recommendations
included blood or catheter cultures (35.9%), serological de-
terminations and/or antifungal levels (19.7%), and radiological
tests (13.9%).
At the initial visit, no change in therapy was deemed
necessary in 68.4% of patients. In the remaining patients, the
most common recommendation was to de-escalate the anti-
fungal drug (17.4%) or to discontinue it (7.1%).
Adequacy of antifungal therapy: ﬁnal evaluation
The ﬁnal evaluation of the clinical charts showed that the mean
point score for antifungal use was 8.64 ± 1.81 (Table 2).Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and InfectOverall, inadequacy in one or more of the features evaluated
was found in 45% of antifungal courses. The most common
problems were inadequate length of therapy (28.5%), inade-
quate choice of antifungal drug (24.1%), and lack of adjustment
to microbiology results (18.5%).
Impact on costs and on antifungal consumption
The annual costs before and after implementation of the AFSP
are presented in Table 3. After 1 year of intervention, the
annual costs were reduced from US$3,817,455 to
US$3,288,292 (13.9% reduction). Subsequently, the imple-
mentation of the bedside intervention was able to reduce
annual costs to US$2,871,497 (12.7% further reduction versus
the previous year). The main antifungals involved in cost
reduction were candins and voriconazole (Table 3). Compared
with the baseline year, and after considering the cost of the
additional staff required, this ﬁnancial beneﬁt generated a net
saving of US$407,663 during the ﬁrst year and of US$824,458 in
the second year.
Monthly costs from October 2007 to September 2013 were
studied in an ITS analysis (see Supporting information). Fig. 1ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 492.e1–492.e9































Candinsa 2 429 734 2 240 574 1 818 254 10.5 10.8 10.6 4129 4097 3649
L-AmBb 624 865 500 279 623 589 2.2 2.1 2.8 883 785 951
Voriconazole 339 064 240 351 177 123 4.0 3.1 3.6 1588 1198 1260
Posaconazole 262 622 218 956 209 152 4.0 3.7 4.0 1570 1402 1375
Fluconazole 99 588 74 467 34 586 40.9 30.4 32.1 16 140 11 563 11 081
Itraconazole 61 311 13 583 8682 2.9 1.1 1.0 1128 417 329
Ketoconazole 270 81 111 2.0 0.6 0.8 778 234 292
ICUs 1 159 049 1 007 039 774 703 336 209 174 5668 3536 2846
Oncology-
haematology
649 972 671 900 441 924 899 695 506 4430 3606 2863
BMTU 578 991 608 436 635 155 953 749 710 2468 1800 1861
Gastroenterology 326 436 117 736 157 167 84 33 59 1858 759 1258
Total 3 817 455 3 288 292 2 871 497 66.4 51.8 54.8 26 216 19 696 18 937
BMTU, bone marrow transplant unit; DDD, deﬁned daily dose; ICU, intensive care unit; L-AmB, liposomal amphotericin B.
aCaspofungin, micafungin, and anidulafungin were grouped as candins.
bDDD for L-AmB = 200 mg.
CMI Valerio et al. Antifungal stewardship 492.e6shows that the overall upward trend of costs that occurred
from October 2007 through September 2010 (before the
AFSP) was reversed after AFSP implementation. The interven-
tion had a signiﬁcant impact after the ﬁrst 12 months of the
intervention and at month 13 the level effect was minus
US$89,927 (p 0.042). From month 14 to month 35 after
intervention the reduction in cost reached minus US$205,860
at month 35 (p 0.006).
The comparison of DDDs of antifungals in the pre-
intervention and intervention periods is also shown in
Table 3. During the second year of intervention, the number of
DDDs consumed/1000 patient-days fell by 17.5% (from 66.4 to
54.8 DDDs) in comparison to the pre-intervention period.
Marked reductions in the prescribed DDDs of ﬂuconazole,
itraconazole and ketoconazole were observed, and prescriptionFIG. 1. Monthly time series of antifungal costs (thousand of US$) from
October 2007 to September 2013. The months are labelled as time
periods from 1 to 72, being the 37th month (October 2010) when the
antifungal stewardship programme was implemented. The ﬁgure shows
the reverse in the trend of cost when the antifungal stewardship was
implemented.
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Inof voriconazole was also reduced by 20.7%. Prescription of oral
voriconazole increased (from 63.2% of total voriconazole
DDDs to 81.1%), as did oral itraconazole (from 46.7% to
73.4%). The overall DDDs of candins decreased by 11.6% and
the DDDs of posaconazole decreased by 12.4% compared with
the pre-intervention period. The only antifungal drug for which
prescriptions did not fall was liposomal amphotericin B.
Impact on quality of care outcomes
We performed an analysis of the most important secondary
clinical outcomes of our programme as shown on Table 4.
Incidence of candidaemia/1000 admissions decreased from
1.49/1000 admissions in 2010 (pre-intervention period) to 1.44/
1000 admissions in 2012 and to 1.14/1000 admissions in 2013.
The reduction was statistically signiﬁcant for Candida albicans
fungaemia. The same occurred with the percentage of ﬂucon-
azole resistance in candidaemia isolates (fell from 6.1% in 2010
to 3.6% in 2013). Overall, candidaemia-related mortality
diminished from 28.0% in 2010 to 16.4% in 2013.DiscussionAn AFSP performed by experienced infectious diseases physi-
cians, pharmacists and clinical microbiologists based on training,
non-compulsory bedside intervention, and daily collaboration
with the pharmacy department could optimize the use of
antifungal drugs in a large tertiary teaching institution. Such a
programme would have a signiﬁcant impact on costs.
Antibiotic stewardship is commonly recommended by most
major scientiﬁc societies. It is designed to ensure optimal use of
antimicrobials and leads to better clinical results, fewer adverse
events, less antibiotic resistance and reduced costs. AFSPs arefectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 492.e1–492.e9
TABLE 4. Impact of the antifungal stewardship on clinical and
demographical characteristics
Pre-AFS During AFS
p2010 2011 2012 2013
Candidaemia incidence/1000 admissions 1.49 1.76 1.44 1.14 0.08
Candidaemia albicans 0.87 0.83 0.67 0.48 0.01
Candidaemia parapsilosis 0.27 0.53 0.38 0.35 0.75
Candidaemia tropicalis 0.09 0.13 0.24 0.12 0.35
Candidaemia glabrata 0.16 0.19 0.16 0.08 0.29
Non-albicans Candida 0.62 0.93 0.77 0.66 0.97
Non-albicans Candida (%) 41.5 52.7 53.5 58.2 0.05
Fluconazole resistance in candidaemia (%) 6.1 4.3 4.2 3.6 0.53
Candidaemia-related mortality (%) 28.0 23.7 22.5 16.4 0.12
Signiﬁcative p values are in bold.
492.e7 Clinical Microbiology and Infection, Volume 21 Number 5, May 2015 CMInot as well developed as antibacterial stewardship programmes
[1]. Antifungal prescription is difﬁcult because of the type of
patient affected, the unspeciﬁc clinical presentation, and the
poor sensitivity of microbiological tests. Furthermore, the high
mortality of IFIs and the evidence that early therapy has an
impact on mortality has led to extended use of empirical and
pre-emptive therapy.
Although approximately 3% of all patients admitted to our
hospital receive a systemic antifungal drug, an IFI could be
proven in only 28.9% of cases. In a study performed in 169
French ICUs, 7.5% of patients were treated with an antifungal
drug; however, even in this high-risk population, an IFI was
demonstrated in only 35% [17].
In our study, which did not include ﬂuconazole, 45% of the
antifungal drugs were prescribed outside the haematology unit
and the ICU. In other centres, this proportion is 30–32% [18,19].
We believe that it is essential to identify the individual needs and
problems of each area of the hospital and that medical and sur-
gical departments are particularly amenable to AFSPs. We found
that targeted therapy was prescribed mainly in medical and
surgical wards, whereas empirical treatment and pre-emptive
treatment were exceptional in these units. Similar ﬁndings
were reported by Bassetti et al., who compared cases of candi-
daemia detected in internal medicine (133/348) with those
occurring in other departments [20] and found that 30-day
mortality was higher in patients with candidaemia in internal
medicine than in other wards (51.1% versus 38.2%, p < 0.02) and
that it was probably related to a high proportion of delayed
treatment (only 7% of therapy was initiated in the ﬁrst 48 h after
the ﬁrst blood culture compared with 25% in other units).
In ICUs, antifungals are mainly used as empiric or pre-
emptive therapy. An echinocandin was used in 88.7% of pre-
emptive courses. As patients commonly have renal or hepatic
insufﬁciency or receive continuous renal replacement therapy,
the bedside intervention may facilitate detection of incorrect
dosages. Swoboda et al. report their experience in a multidis-
ciplinary ICU in which all members agreed to follow a ﬂowchartClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectfor using antifungals. The programme resulted in a 50%
reduction in antifungal cost, even though the severity and
number of admissions did not change. The reduction was
mainly due to reduced consumption of caspofungin and vor-
iconazole [4]. Another successful example of an antifungal
bundle in an ICU was published by Guarascio et al., who also
demonstrated the potential cost savings of discontinuing
empirical therapy and de-escalation from caspofungin to ﬂu-
conazole [8]. In these departments, efforts should be aimed at
improving de-escalation based on microbiological data, avoiding
unnecessarily prolonged therapy, and switching to oral therapy
when possible. In our experience, the number of antifungal
DDDs prescribed by ICUs decreased by 49.8%. Associated
costs were also reduced.
In haematology departments, antifungal therapy is mainly
prescribed as prophylaxis (75.6% of all antifungal prescriptions).
In our institution, haematologists participated in the AFSP and
became more aware of the importance of avoiding prolonged
prophylaxis and the beneﬁt of evaluating the individual need for
antifungals day by day. Another important objective in the
haematology department is to guide empirical therapy (which
represents 21.2% of all antifungal prescriptions) with more
efﬁcacious radiology and microbiology studies (diagnosis-driven
approach). A very useful ﬂow-chart was proposed by Aguilar-
Guisado et al., who applied a simple diagnostic approach by
avoiding the use of antifungal drugs in 62% of febrile neu-
tropenic patients [21] All IFIs (14.1%) occurred in patients who
had received empirical antifungal therapy, and the IFI-related
mortality rate was 2.8% (2/72). Similar positive results have
also been published by other authors [22]. In our experience,
the use of antifungal drugs decreased by 24.6% in the bone
marrow transplant unit and by 35.4% in general oncology-
haematology wards.
Adequacy of antifungal therapy: ﬁnal evaluation
Antifungal stewardship programmes are expected to optimize
prescription of antifungal drugs and to improve the diagnosis of
fungal infections and the quality of care. Our study demon-
strates that at the ﬁrst bedside assessment, a diagnostic sug-
gestion was necessary in 40% of the patients and that therapy
had to be modiﬁed in 30%. Mondain et al. demonstrated that an
AFSP based on a complete bundle of measures improved the
quality of care in candidaemia and invasive aspergillosis and
reduced overall mortality [7]. Similar results were found by
Antworth et al., who implemented a comprehensive care
bundle for the management of candidaemia in a US hospital. The
candidaemia care team obtained a signiﬁcant improvement in
adherence to the three measures in the bundle: appropriate
therapy after microbiological results, ophthalmological exami-
nation performed, and appropriate duration of therapy [23].ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 492.e1–492.e9
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prescription at the ﬁrst bedside visit (4.4%), because we start
empirical therapy in infected patients with risk factors and no
established diagnosis. This ﬁnding was also reported by Raymond
et al., who performed an audit of the use of expensive systemic
antifungals and found that therapy was correctly initiated in 92%
of cases [24]. However, selection of the antifungal drug was often
considered inadequate, and in 24.1% of cases it was non-optimal.
Raymond et al. found that 54% of prescriptions were inadequate
according to international guidelines [24]. In our experience, the
rate of inadequacy in any of the aspects considered (indication,
drug, dosage, administration route, adjustments, and duration)
was 45% and was judged in terms of our local guidelines based on
local epidemiology and resistance rates. We observed that de-
escalation was a signiﬁcant issue for AFSPs. In our study, the
response of antifungal prescribers to microbiological evidence
was not always positive, and no subsequent adjustments were
made in 18.5% of cases.
Another goal of an AFSP is to minimize complications by
optimizing the dose and duration of therapy. Inadequate dosage
was recorded in 3.8% of cases and probable antifungal-related
toxicity in 6.8%. Patients could beneﬁt from a bedside inter-
vention that identiﬁes antifungal-related toxicity and potential
medication interactions and suggests therapeutic drug moni-
toring. Ananda-Rajah et al. also concludes that toxicities of
antifungal agents are part of the rationale for AFSPs [1].
Finally, another important objective of our intervention was
to reduce unnecessarily prolonged therapy: length of therapy
was inadequate in 28.5% of patients.
Economic impact and potential cost savings
Our non-compulsory programme made it possible to reduce
antifungal expenditure without complications in patients whose
drugs were switched or discontinued. The main component of
the cost savings was the reduction in the use of candins in
haematology (from 101 to 62 DDD/1000 patient-days) and in
the ICUs (from 88 to 76 DDD/1000 patient-days). Compared
with the pre-intervention period, total antifungal expenditure
was reduced by 32% (–US$208,048) and 33% (–US$384,346)
during the second year of intervention, respectively. These
savings resulted from more restricted use of prophylaxis in
patients receiving remission-induction chemotherapy for acute
myeloid leukaemia or myelodysplastic syndromes and empirical
treatment in critical patients with a low percentage of infections
by ﬂuconazole-resistant Candida. The AFSP also led to a sig-
niﬁcant reduction in the prescription of voriconazole and
increased use of the oral formulation (low cost and excellent
bioavailability). Interestingly, our educational and bed-side
intervention also led to a reduced use of non-targeted drugs
such as ﬂuconazole.Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and InIt is difﬁcult to compare our data with those from other
hospitals because the literature contains few studies on anti-
fungal stewardship. After implementation of the AFSP, total
antifungal use in our hospital was 55 DDDs per 1000 patient-
days, which is lower than the post-intervention 100–120
DDDs per 1000 patient-days reported elsewhere [5,25]. Api-
sarnthanarak et al. reported 117 DDDs per 1000 patient-days
for ﬂuconazole only [3], and López-Medrano et al. reported
296 DDDs per 1000 patient-days for voriconazole, caspofungin
and liposomal amphotericin B [6]. Only the study of Mondain
et al. [7] demonstrated lower consumption of antifungals during
a 6-year AFSP (always <40 DDD per 1000 patient-days with a
cost of <US$2 million).
Although our programme failed to reduce the use of lipo-
somal amphotericin B, it is important to remember that this is
the drug of choice for leishmaniasis, which is a common para-
sitic disease in Spain. In fact, 31.6% of prescriptions of liposomal
amphotericin B were for leishmaniasis. In the other existing
study of AFSP in Spain, use of amphotericin B was also unaf-
fected by the programme (increase of 13.9%) [6].
Regarding secondary outcomes, our programme helped to
reduce candidaemia-related mortality, candidaemia incidence
and ﬂuconazole resistance.
Our study is subject to a series of limitations. First, drug prices
may differ from the ofﬁcially established price, owing to dis-
counts negotiated with drug suppliers. As drug prices can vary
throughout the study, we cannot rule out a small impact on our
results. Second, although the purchase price and drug mark-ups
were included in our cost estimates, we acknowledge an un-
derestimation of costs due to the exclusion of administration
costs. Third, we could not target ﬂuconazole due to staff limi-
tation, although its use was also reduced during the intervention.
Finally, ours is a single-centre study, although we believe that our
results may be extensible to similar teaching, tertiary institutions.
In conclusion, a collaborative and non-compulsory stew-
ardship programme based on bedside intervention is an efﬁ-
cacious and cost-effective approach for optimizing the use of
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